Qlucore Receives Approval for 0.5M EUR Installment from the EU
24 juni, 14:00
Qlucore, a leader in software development for precision cancer diagnostics, received a prestigious grant of 2.5 million Euros during 2024. The grant is divided into four installments. The aim of the project is to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer. Within the agreed twelve-month timeframe, Qlucore has passed all the milestones set out for the first part of the project. After passing review, the second payment from the EU of approximately 0.5 million Euros can therefore be processed.
During the project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics for AML and bladder cancer. The project spans over three years. The aim is to develop tests for use in clinical laboratories. Another focus is, in collaboration with the pharmaceutical industry, to develop solutions for companion diagnostics.
AML and bladder cancer are of special interest to the project. This is because they harbor multiple RNA modifications. These changes can be utilized to improve diagnosis and treatment. Currently, this information is not fully applied to ensure that the right treatment is used for the right patient. This project aims to change this.
For a medical device to be used in healthcare diagnostics, IVDR regulations require the device to have CE marking. For this project, Qlucore will build on significant investments in its solutions for acute lymphoblastic leukemia, Qlucore Diagnostics BCP-ALL, both from a software technical point of view and from a quality management system (QMS) point of view. Qlucore Diagnostics BCP-ALL 1.0 was launched in February and has already been sold to the first customer.
“This EU payment will strengthen Qlucore financially. We are at the forefront of RNA-seq-based modern clinical diagnostics and we will continue to work with the milestones set out for this project." says Carl-Johan Ivarsson, CEO of Qlucore.
Intended customers are clinical laboratories across Europe in the first phase, and the US market in the second phase.
Certified Advisor
FNCA Sweden AB
Web: www.fnca.se
Contacts
Press contact:
Maria Falck Miniotis, Marketing & Communications Manager
Phone: +46 (0) 736 10 26 65
Email: maria.falck@qlucore.com
Carl-Johan Ivarsson, CEO
Phone: +46 (0) 46 286 31 10
Email: carl-johan.ivarsson@qlucore.com
About Qlucore
Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market. www.qlucore.com
Attachments
Qlucore Receives Approval for 0.5M EUR Installment from the EU
Ämnen i artikeln
Qlucore Receives Approval for 0.5M EUR Installment from the EU
24 juni, 14:00
Qlucore, a leader in software development for precision cancer diagnostics, received a prestigious grant of 2.5 million Euros during 2024. The grant is divided into four installments. The aim of the project is to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer. Within the agreed twelve-month timeframe, Qlucore has passed all the milestones set out for the first part of the project. After passing review, the second payment from the EU of approximately 0.5 million Euros can therefore be processed.
During the project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics for AML and bladder cancer. The project spans over three years. The aim is to develop tests for use in clinical laboratories. Another focus is, in collaboration with the pharmaceutical industry, to develop solutions for companion diagnostics.
AML and bladder cancer are of special interest to the project. This is because they harbor multiple RNA modifications. These changes can be utilized to improve diagnosis and treatment. Currently, this information is not fully applied to ensure that the right treatment is used for the right patient. This project aims to change this.
For a medical device to be used in healthcare diagnostics, IVDR regulations require the device to have CE marking. For this project, Qlucore will build on significant investments in its solutions for acute lymphoblastic leukemia, Qlucore Diagnostics BCP-ALL, both from a software technical point of view and from a quality management system (QMS) point of view. Qlucore Diagnostics BCP-ALL 1.0 was launched in February and has already been sold to the first customer.
“This EU payment will strengthen Qlucore financially. We are at the forefront of RNA-seq-based modern clinical diagnostics and we will continue to work with the milestones set out for this project." says Carl-Johan Ivarsson, CEO of Qlucore.
Intended customers are clinical laboratories across Europe in the first phase, and the US market in the second phase.
Certified Advisor
FNCA Sweden AB
Web: www.fnca.se
Contacts
Press contact:
Maria Falck Miniotis, Marketing & Communications Manager
Phone: +46 (0) 736 10 26 65
Email: maria.falck@qlucore.com
Carl-Johan Ivarsson, CEO
Phone: +46 (0) 46 286 31 10
Email: carl-johan.ivarsson@qlucore.com
About Qlucore
Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market. www.qlucore.com
Attachments
Qlucore Receives Approval for 0.5M EUR Installment from the EU
Ämnen i artikeln
Novo Nordisk
Aktieråd
-992x558.webp&w=3840&q=75)
Analys
Bostadsmarknaden
Novo Nordisk
Aktieråd
Analys
Bostadsmarknaden
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
